Peptide Based Imaging Agents for HER2 Imaging in Oncology
Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-09-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.1177/1536012120960258 |
| _version_ | 1826910918759415808 |
|---|---|
| author | Maxwell Ducharme Suzanne E. Lapi PhD |
| author_facet | Maxwell Ducharme Suzanne E. Lapi PhD |
| author_sort | Maxwell Ducharme |
| collection | DOAJ |
| description | Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has approved receptor-based therapies including trastuzumab and pertuzumab that can significantly increase the likelihood of survival. Current methods to determine HER2 status include biopsies with immunohistochemical staining and/or fluorescence in situ hybridization. However, positron emission tomography (PET) imaging techniques using 89 Zr-trastuzumab or 89 Zr-pertuzumab are currently in clinical trials for a non-invasive, full body diagnostic approach. Although the antibodies have strong specificity to the HER2 positive lesions, challenges involving long post-injection time for imaging due to the blood circulation of the antibodies and matching of long-live isotopes leading to increased dose to the patient leave opportunities for alternative PET imaging probes. Peptides have been shown to allow for shorter injection-to-imaging time and can be used with shorter lived isotopes. HER2 specific peptides under development will help improve the diagnosis and potentially therapy options for HER2 positive breast cancer. Peptides showing specificity for HER2 could start widespread development of molecular imaging techniques for HER2 positive cancers. |
| first_indexed | 2024-03-07T17:29:04Z |
| format | Article |
| id | doaj.art-52ccf6fb0efc4f6294c2fd6f70cdc851 |
| institution | Directory Open Access Journal |
| issn | 1536-0121 |
| language | English |
| last_indexed | 2025-02-17T10:07:01Z |
| publishDate | 2020-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj.art-52ccf6fb0efc4f6294c2fd6f70cdc8512025-01-02T02:58:13ZengSAGE PublishingMolecular Imaging1536-01212020-09-011910.1177/1536012120960258Peptide Based Imaging Agents for HER2 Imaging in OncologyMaxwell Ducharme0Suzanne E. Lapi PhD1 Department of Radiology, , Birmingham, AL, USA Department of Radiology, , Birmingham, AL, USABreast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has approved receptor-based therapies including trastuzumab and pertuzumab that can significantly increase the likelihood of survival. Current methods to determine HER2 status include biopsies with immunohistochemical staining and/or fluorescence in situ hybridization. However, positron emission tomography (PET) imaging techniques using 89 Zr-trastuzumab or 89 Zr-pertuzumab are currently in clinical trials for a non-invasive, full body diagnostic approach. Although the antibodies have strong specificity to the HER2 positive lesions, challenges involving long post-injection time for imaging due to the blood circulation of the antibodies and matching of long-live isotopes leading to increased dose to the patient leave opportunities for alternative PET imaging probes. Peptides have been shown to allow for shorter injection-to-imaging time and can be used with shorter lived isotopes. HER2 specific peptides under development will help improve the diagnosis and potentially therapy options for HER2 positive breast cancer. Peptides showing specificity for HER2 could start widespread development of molecular imaging techniques for HER2 positive cancers.https://doi.org/10.1177/1536012120960258 |
| spellingShingle | Maxwell Ducharme Suzanne E. Lapi PhD Peptide Based Imaging Agents for HER2 Imaging in Oncology Molecular Imaging |
| title | Peptide Based Imaging Agents for HER2 Imaging in Oncology |
| title_full | Peptide Based Imaging Agents for HER2 Imaging in Oncology |
| title_fullStr | Peptide Based Imaging Agents for HER2 Imaging in Oncology |
| title_full_unstemmed | Peptide Based Imaging Agents for HER2 Imaging in Oncology |
| title_short | Peptide Based Imaging Agents for HER2 Imaging in Oncology |
| title_sort | peptide based imaging agents for her2 imaging in oncology |
| url | https://doi.org/10.1177/1536012120960258 |
| work_keys_str_mv | AT maxwellducharme peptidebasedimagingagentsforher2imaginginoncology AT suzanneelapiphd peptidebasedimagingagentsforher2imaginginoncology |